{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:38:58Z","timestamp":1792762738298,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"21","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To describe a case of severe acute hepatitis in an adolescent in whom fosfomycin was identified as the highly probable cause of drug-induced liver injury (DILI) and to highlight the potential hepatotoxicity of fosfomycin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A previously healthy 17-year-old male presented with nausea, vomiting, fever, and progressive epigastric pain over 3 days, accompanied by fatigue and malaise. Laboratory testing revealed marked hepatocellular injury, coagulopathy, metabolic acidosis, mild pre-renal acute kidney injury, and elevated inflammatory markers. Imaging demonstrated hepatomegaly with ascites, without biliary obstruction or vascular abnormalities. Extensive evaluation excluded viral hepatitis, autoimmune liver disease, Wilson\u2019s disease, ischemic hepatitis, zoonotic infections, and other potential hepatotoxic exposures. Within the 15 days before symptom onset, the patient had completed a 7-day course of oral fosfomycin 500 mg every 8 hours for renal colic\u2013associated dysuria, with no other medications linked to liver injury. Clinical deterioration with hypotension and oliguria required admission to the intensive care unit, where the patient improved with supportive management during a 4-day stay. Using the Roussel-Uclaf Causality Assessment Method (RUCAM), the score was 9, indicating a highly probable association between fosfomycin and the liver injury. Levels of liver enzymes gradually normalized, and the patient was discharged with full recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although fosfomycin is widely used and generally well tolerated, clinicians should remain vigilant for this rare but potentially serious adverse effect. Early recognition and prompt discontinuation of the suspected agent are essential. Reporting uncommon adverse reactions helps strengthen pharmacovigilance and supports safer therapeutic decision-making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag162","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T11:34:26Z","timestamp":1780832066000},"page":"e799-e804","source":"Crossref","is-referenced-by-count":0,"title":["Fosfomycin-induced liver injury in a 17-year-old patient: A case report"],"prefix":"10.1093","volume":"83","author":[{"given":"Estefan\u00eda","family":"Palaz\u00f3n Gonz\u00e1lvez","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Morales Meseguer University General Hospital , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Dolores","family":"N\u00e1jera P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Morales Meseguer University General Hospital , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Alegr\u00eda Samper","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Morales Meseguer University General Hospital , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"issue":"11","key":"2026102308563168600_zxag162-B1","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2026102308563168600_zxag162-B2","author":"National Library of Medicine"},{"issue":"4","key":"2026102308563168600_zxag162-B3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40121-015-0092-8","article-title":"Adverse events associated with fosfomycin use: review of the literature and analyses of the FDA Adverse Event Reporting System database","volume":"4","author":"Iarikov","year":"2015","journal-title":"Infect Dis Ther"},{"issue":"4","key":"2026102308563168600_zxag162-B4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics6040024","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics"},{"issue":"6","key":"2026102308563168600_zxag162-B5","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"key":"2026102308563168600_zxag162-B6","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","author":"National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"issue":"9","key":"2026102308563168600_zxag162-B7","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.11405\/nisshoshi.102.1207","article-title":"A case of acute severe hepatitis induced by fosfomycin","volume":"102","author":"Matsumori","year":"2005","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"issue":"3","key":"2026102308563168600_zxag162-B8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1751-2980.2009.00385.x","article-title":"Drug-induced liver disease: an 8-year study of patients from one gastroenterological department","volume":"10","author":"Wang","year":"2009","journal-title":"J Dig Dis"},{"issue":"5","key":"2026102308563168600_zxag162-B9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/003655401750174200","article-title":"Acute, recurrent fosfomycin-induced liver toxicity in an adult patient with cystic fibrosis","volume":"33","author":"Durupt","year":"2001","journal-title":"Scand J Infect Dis"},{"issue":"5","key":"2026102308563168600_zxag162-B10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jpg.2012.04.003","article-title":"Acute hepatitis induced by fosfomycin: a case report and review of the literature","volume":"19","author":"Ferreira","year":"2012","journal-title":"GE J Port Gastrenterol"},{"issue":"3","key":"2026102308563168600_zxag162-B11","doi-asserted-by":"publisher","first-page":"e55508","DOI":"10.7759\/cureus.55508","article-title":"Fosfomycin-induced liver injury: a case report","volume":"16","author":"Ribeiro","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"2026102308563168600_zxag162-B12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.rgmx.2023.04.008","article-title":"El m\u00e9todo de evaluaci\u00f3n de causalidad de hepatotoxicidad de Roussel\u2014Uclaf en el contexto de sospecha diagn\u00f3stica de da\u00f1o hep\u00e1tico inducido por medicamentos: \u00bfes a\u00fan vigente?","volume":"88","author":"S\u00e1nchez Luque","year":"2023","journal-title":"Rev Gastroenterol Mex"},{"issue":"6","key":"2026102308563168600_zxag162-B13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/gutjnl-2016-313369","article-title":"Drug-induced liver injury: recent advances in diagnosis and risk assessment","volume":"66","author":"Kullak-Ublick","year":"2017","journal-title":"Gut"},{"key":"2026102308563168600_zxag162-B14","author":"Machancoses"},{"issue":"1","key":"2026102308563168600_zxag162-B15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2017-314924","article-title":"Guidelines on the management of abnormal liver blood tests","volume":"67","author":"Newsome","year":"2017","journal-title":"Gut"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag162\/68490896\/zxag162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/21\/e799\/68490896\/zxag162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/21\/e799\/68490896\/zxag162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:56:41Z","timestamp":1792760201000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/21\/e799\/8704023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":15,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,10,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag162","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,1]]},"published":{"date-parts":[[2026,6,8]]}}}